A new study by scientists from the Institute of La JOLLA immunology (LJI), and the medical center of Erasmus University (Erasmus) shows that even the most ill COVID-19 patients to produce T cells that help to fight the virus. The study offers new evidence that COVID-19 vaccine is necessary to cause T-cells to work together with the antibodies.
A study published June 26 in science Immunology, also shows that both Dutch and American patients have the same reaction to the virus. “This is the key to understanding how the immune system fights the virus,” says Professor LJI Alessandro Sette, Dr. Biol. Ekon. Sciences, who Co-led the study with Erasmus virologist Rory de Vries, Ph. D. “required vaccine approaches should be based on observations with different conditions, to ensure that the results are generally applicable.”
For the study, the researchers tracked ten COVID-19 patients with the most severe symptoms of the disease. All ten of them were hospitalized in the ICU of the Medical center of Erasmus University in the Netherlands, and put on the fans as part of their service. Two of the patients eventually died from the disease. An in-depth look at their immune system showed that all ten patients produced T-cells that target SARS-cov-2 virus. These T-cells work together with antibodies to try to clear the virus and stop the infection.
These findings are in line with the results of recent studies of cells from Sette, Professor LJI Shane crotty, Ph. D., LJI and colleagues, which showed a robust T cell response in patients with moderate cases COVID-19. In both studies, T cells in these patients deliberate emphasis of the spike protein in SARS-cov-2. The virus uses the spike protein to enter host cells, many vaccine efforts in the world aimed at getting the immune system to recognize and attack the protein. A new study offers new evidence that the spike protein is a promising target and confirms that the immune system can also mount a strong response to more virus.
“This is good news for those who make vaccines, using spike and it also offers new opportunities for potential increase potency of the vaccine,” says Daniela Weiskopf, Ph. D., research associate Professor at LJI and the first author of the new study.
Cooperation between scientists in La JOLLA and the Netherlands are also part of the overall picture and highlights the close cooperation of the philosophy adopted by the group LJI. Sette is a world leader in understanding what specific pieces (or antigens), the immune system recognizes when he is facing new germs. Work in the laboratory of Sette in the definition of epitope sets that allow you to measure SARS-cov-2 T-cell responses is a key element of the study.
In fact, LJI has become the center COVID-19 T cell research, and Sette sent reagents for more than 60 laboratories around the world. “The study is also very important because it shows how the science has no borders,” says Sette. “To truly understand a global pandemic, our approach must be global, and we need to study immune responses in people with different genetic backgrounds, living in different environments.”
Despite the cell paper, followed residents of San Diego, the new document follows the Dutch patients And T-cell responses were consistent in both populations. “This study is important because it shows that the immune response in patients thousands of kilometers away from each other,” says Weiskopf. “The same observation was heavily played on different continents and different research.”
In a study titled “phenotype and Kinetics of SARS-cov-2-specific T-cells in COVID-19 patients with acute respiratory distress syndrome” was supported by the European Union’s Horizon 2020 research and innovation programme (grant agreements No. 874735) National institutes of health (contract # 75N9301900065.)
Additional studies include Katherine C. Schmitz, Mathis P. Raadsen, Alba Grifoni, Nisreen A. M. Okba, Henrik Endeman, P. S. Johannes van den Akker, Richard Molenkamp, Marion P. G. Koopmans, Eric C. M. van Gorp, Bart L. Haagmans and Rik L. de Swart.